Find a peptide by what it helps with

A once-weekly GLP-1 receptor agonist for weight management and metabolic health.

• Significant and sustained weight loss
• Improved blood sugar regulation
• Reduced cardiovascular risk markers

A once-weekly dual GIP and GLP-1 receptor agonist delivering superior weight loss and metabolic improvements compared to GLP-1 monotherapy.

• Greater average weight loss vs. semaglutide
• Improved blood sugar control
• Reduced appetite and cravings

Daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, up to 1.8 mg/day) and chronic weight management (Saxenda, up to 3.0 mg/day). Slows gastric emptying, increases satiety, improves glycemic control, and reduces cardiovascular events in T2D.

• Sustained weight loss
• A1C reduction in T2D
• Appetite suppression and reduced food cravings

A synthetic peptide with potent tissue-healing, gut-protective, and anti-inflammatory properties. Widely used for injury recovery and gut health.

• Accelerated tendon and ligament healing
• Reduced joint pain and inflammation
• Improved gut health

Synthetic 17–amino-acid fragment of the naturally occurring Thymosin Beta-4 protein. Drives actin polymerization, accelerates wound and soft-tissue repair, and modulates inflammation through actin sequestration in injured tissue.

• Soft-tissue and tendon repair
• Reduced inflammation at injury site
• Improved range of motion in chronic injury

A synergistic growth hormone releasing combination for body composition, sleep, and recovery.

• Increased lean muscle mass
• Reduced body fat
• Deeper, more restorative sleep

Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.

• Increased lean body mass
• Deeper sleep and improved REM
• Improved fat metabolism, especially visceral

Synthetic GHRH analog (modified GHRH 1-44) FDA-approved as Egrifta for HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue and modestly elevates IGF-1 with a favorable safety profile relative to exogenous HGH.

• Visceral adipose tissue reduction
• Improved triglyceride and lipid profile
• Modest IGF-1 elevation

A regenerative peptide blend targeting skin quality, tissue repair, and systemic recovery.

• Improved skin elasticity and texture
• Accelerated tissue and wound healing
• Reduced inflammation

A melanocortin receptor agonist that enhances sexual desire and arousal in both men and women by acting centrally via the nervous system.

• Increased sexual desire and libido
• Enhanced arousal in men and women
• Acts via CNS — works regardless of hormonal status

Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).

• Increased lean body mass
• Visceral and subcutaneous fat loss
• Faster recovery from training and injury

Glycoprotein hormone produced during pregnancy. Mimics luteinizing hormone (LH), stimulating Leydig cells in the testes to produce testosterone and maintain testicular volume. Commonly co-administered with TRT to preserve fertility and prevent testicular atrophy, or used as a post-cycle/restart bridge.

• Testicular size preservation on TRT
• Maintains intratesticular testosterone
• Fertility preservation during exogenous testosterone use

Pre-dissolved at U-100 concentration (100 IU/mL). Units on a U-100 insulin syringe map 1:1 to draw volume in mL × 100. Insulin is FDA-approved for diabetes management and must be used under medical supervision. Off-label use for nutrient partitioning carries severe hypoglycemia risk and is not recommended.

• Blood glucose control
• Postprandial glycemic regulation

Skytrofa is a once-weekly, long-acting growth hormone for children with growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug that slowly releases somatropin (hGH) over 7 days, providing stable GH levels with a single weekly injection instead of daily shots.

• Linear growth acceleration in GH-deficient children
• Once-weekly convenience vs. daily injections
• Stable, sustained GH/IGF-1 levels throughout the week

Testosterone replacement therapy using a long-acting ester for stable hormone levels.

• Restored testosterone levels
• Improved energy and vitality
• Increased muscle mass and strength

A synthetic hexapeptide that binds the ghrelin/GHS-R1a receptor to stimulate pulsatile growth hormone release from the anterior pituitary. Researched for GH deficiency, cachexia, and tissue-protective effects; also a potent appetite stimulant.

• Stimulates pulsatile GH and IGF-1 release
• Increases appetite via ghrelin pathway
• May support recovery and lean tissue

An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.

• Sustained 24-hour GH and IGF-1 elevation
• Increased fat-free mass over 12 months
• Improved stage IV and REM sleep quality

A 28-amino-acid synthetic copy of a naturally occurring thymic peptide. Acts as an immune-system modulator (not a growth-hormone or anabolic peptide) by influencing T-cell maturation and innate immunity. Approved abroad as Zadaxin in 35+ countries for chronic hepatitis B and as an adjuvant in oncology — not FDA-approved in the US for general use. Typically cycled 6–12 weeks.

• Restores and modulates T-cell function
• Enhances vaccine response
• Supports immune resilience in immunocompromised states

The active C-terminal fragment of the human cathelicidin precursor hCAP-18. Shows broad antimicrobial activity against Gram-positive and Gram-negative bacteria plus biofilms, and is involved in keratinocyte migration and re-epithelialization in wound healing.

• Broad antimicrobial activity (Gram±, biofilms)
• Promotes keratinocyte migration and wound closure
• Activates EGFR-mediated re-epithelialization

A nine-amino-acid neuropeptide explored in research as an intranasal spray for social cognition, anxiety, and bonding effects. This entry reflects research-protocol intranasal microdosing only — distinct from obstetric IV oxytocin used during labor.

• May enhance affective empathy and social engagement
• Reduces self-reported social anxiety in some trials
• Studied as adjunct to exposure therapy

A synthetic decapeptide identical to native GnRH that triggers pituitary LH and FSH release, downstream stimulating endogenous testosterone and spermatogenesis. Used adjunctively in TRT to preserve testicular function and in hypogonadotropic hypogonadism via pulsatile dosing.

• Maintains testicular size during TRT
• Stimulates pituitary LH and FSH release
• Supports endogenous testosterone in HPG axis

A synthetic tripeptide (Glu-Asp-Arg) from Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation. Animal studies report reduced ROS in cerebellar granule and PC12 cells, plus improved cognitive outcomes in prenatal hyperhomocysteinemia and Alzheimer's mouse models.

• Reduces ROS in neuronal cells (preclinical)
• Neuroprotective in oxidative-stress models
• Improved offspring cognition in prenatal stress models

A 28-amino-acid neuropeptide signaling through VPAC1/VPAC2 receptors. Established anti-inflammatory and immunomodulatory effects across innate and adaptive immunity. Used clinically off-label as an intranasal preparation in chronic inflammatory response syndrome (CIRS) protocols.

• Suppresses pro-inflammatory cytokine production
• Induces regulatory T-cell phenotypes
• Studied for sepsis, RA, Crohn's, MS (preclinical)

A tripeptide corresponding to the C-terminal fragment of α-melanocyte-stimulating hormone (Lys-Pro-Val). Anti-inflammatory in vitro and in vivo via PepT1-mediated cellular uptake (not melanocortin receptor signaling), with nanomolar inhibition of NF-κB and MAP kinase pathways.

• Inhibits NF-κB and MAP kinase signaling
• Reduces pro-inflammatory cytokine secretion
• Reduced disease severity in DSS/TNBS colitis models

A regenerative, anti-inflammatory peptide blend that adds KPV to the GLOW base (GHK-Cu, BPC-157, TB-500) for extra immune and gut-inflammation support alongside skin quality and tissue repair.

• Improved skin elasticity and texture
• Accelerated tissue and wound healing
• Reduced systemic and gut inflammation

An orally active non-steroidal selective estrogen receptor modulator (SERM) — the trans-isomer of clomiphene. Enclomiphene blocks estrogen feedback at the hypothalamus and pituitary, raising LH and FSH so the testes produce more of the body’s own testosterone. Unlike injected testosterone, it preserves testicular function and fertility, which makes it a common choice for younger men with secondary hypogonadism. Not FDA-approved; prescribed off-label, typically through compounding pharmacies.

• Raises total and free testosterone without injections
• Preserves fertility and testicular size
• Restores LH and FSH toward the normal range

An oral non-steroidal aromatase inhibitor. Anastrozole blocks the aromatase enzyme that converts testosterone into estradiol, lowering circulating estrogen. In testosterone therapy it is used off-label to manage estrogen-related effects — water retention, gynecomastia risk, and mood swings — when estradiol runs high. Its FDA-approved indication is hormone-receptor-positive breast cancer in postmenopausal women (brand name Arimidex). Because estrogen is important for bone density, lipids, and libido, anastrozole is dosed conservatively and ideally guided by bloodwork.

• Lowers estradiol when it runs high on testosterone therapy
• Reduces estrogen-related water retention and bloating
• Helps manage gynecomastia risk